retatrutide clinical trial dose retatrutide Dosing: Early Insights on How It Might Work Phase III retatrutide study demonstrates

Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J, et al

Description Research Summary: S (GLP-1 S) is a selective GLP-1 receptor agonist with 94% homology to native GLP-1

If lyophilized, you need to reconstitute tirzepatide with bacteriostatic water before use

People who are pregnant, breastfeeding, or planning pregnancy should avoid retatrutide, along with those who have a personal or family history of thyroid cancer or previous pancreatitis

Since retatrutide is a weekly injection, the daily tesamorelin schedule would continue independently

published the results of a phase 3 clinical trial of tirzepatide, a dual GIP and GLP-1 receptor agonist, in patients with T2DM, showing significant results in glycemic control and weight loss (Rosenstock et al., 2021)